ALPMF
Stock Details
ALPMF is Astellas Pharma Inc.'s stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 14.36$. Average daily volumn in 3 months 2.22k. Market cap 26.01B
Stock symbol : ALPMF. Exchange : Other OTC. Currency : USD Lastest price : 14.28$. Total volume : 370.00. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Astellas Pharma Inc. (ALPMF)
Last Price
14.28$Change
0.00Volume
370.00
| Previous Close | 14.28 |
| Open | 14.28 |
| Day Range | 14.28-14.28 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Volume | 370 |
| Average Volume | 2.22k |
| Market Cap | 26.01B |
| Beta | 0.55 |
| 52 Week Range | 12.77-16.71 |
| Trailing P/E | 25.05 |
| Foward P/E | N/A |
| Dividend (Yield %) | 3.30% |
| Ex-Dividend Date | 2023-03-30 |
Financial Details
Organization
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adre... nergic receptor agonist for the treatment of overactive bladder urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Market Cap:
26.01BRevenue:
1.3TTotal Assets:
2.33TTotal Cash:
315.99B
News about "Astellas Pharma Inc."
Japanese Government Urges China To Release Astellas Pharma's Employee
Source from : Benzinga on MSN - 5 days ago
The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities. The reasons why the person was ...See details»
Japanese Man Detained in China Is Astellas Pharma Employee
Source from : U.S. News & World Report - 6 days ago
TOKYO (Reuters) -A Japanese man detained in China is an employee of Astellas Pharma Inc, a company spokesperson told Reuters on Sunday. The company did not identify the employee and the ...See details»
China Detains Employee of Japanese Drugmaker Astellas
Source from : Bloomberg L.P. - 5 days ago
The Japanese government is seeking the release of an employee of Japanese drugmaker Astellas Pharma Inc. detained by Chinese authorities. The company is working with Japan’s foreign ministry ...See details»
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
Source from : Business Insider - 10 days ago
Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with ...See details»
Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar
Source from : Business Insider - 3 days ago
(RTTNews) - Astellas Pharma Inc. said that it has reached an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's Accu-Chek Guide ...See details»
Japan demands China release Astellas Pharma employee accused of spying
Source from : BBC - 3 days ago
Astellas Pharma confirmed that the man was its employee but refused to divulge his identity. In 2019, China detained a Japanese professor who specialises in modern Chinese history on suspicion of ...See details»
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
Source from : Benzinga.com - 23 days ago
TOKYO and ROCKVILLE, Md., March 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and the Blood and ...See details»
Japan Seeks Release of Drugmaker’s Worker Detained in China
Source from : Yahoo News - 5 days ago
(Bloomberg) -- The Japanese government is seeking the release of an employee of Japanese drugmaker Astellas Pharma Inc. detained by Chinese authorities. Most Read from Bloomberg FBI Releases Files on ...See details»
Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint
Source from : Benzinga.com - 18 days ago
TOKYO, March 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the Phase 3 China ARCHES ...See details»
Astellas : Phase 3 Study Of Xtandi In Metastatic Hormone-sensitive Prostate Cancer Meets Main Goal
Source from : Nasdaq - 19 days ago
(RTTNews) - Astellas Pharma Inc. (ALPMY) announced positive results from the Phase 3 China ARCHES study of Xtandi (enzalutamide) plus androgen deprivation therapy in men with metastatic hormone ...See details»
Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar
Source from : Nasdaq - 4 days ago
(RTTNews) - Astellas Pharma Inc. said that it has reached an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's Accu-Chek Guide ...See details»
Japanese man detained in China is Astellas Pharma employee
Source from : Yahoo News - 6 days ago
TOKYO (Reuters) -A Japanese man detained in China is an employee of Astellas Pharma Inc, a company spokesperson told Reuters on Sunday. The company did not identify the employee and the spokesperson ...See details»
Astellas presents positive results from phase 3 GLOW trial of zolbetuximab plus Capox during March ASCO plenary series
Source from : Pharmabiz - 9 days ago
Astellas presents positive results from phase 3 GLOW trial of zolbetuximab plus Capox during March ASCO plenary series: Tokyo Thursday, March 23, 2023, 15:00 Hrs [IST] Astellas Ph ...See details»
Astellas’ phase 3 China ARCHES study of Xtandi plus ADT in men with mHSPC meets primary endpoint
Source from : Pharmabiz - 17 days ago
Astellas Pharma Inc. announced positive topline results from the phase 3 China ARCHES study of Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive ...See details»